Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Net Income towards Common Stockholders rose 12846.91% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 14415.3%. This contributed to the annual value of -$64.0 million for FY2024, which is 1594.04% down from last year.
  • Latest data reveals that Theravance Biopharma reported Net Income towards Common Stockholders of $3.6 million as of Q3 2025, which was up 12846.91% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Net Income towards Common Stockholders registered a high of $927.1 million during Q3 2022, and its lowest value of -$23.1 million during Q4 2024.
  • Its 5-year average for Net Income towards Common Stockholders is $50.3 million, with a median of $3.6 million in 2025.
  • As far as peak fluctuations go, Theravance Biopharma's Net Income towards Common Stockholders surged by 440000.49% in 2022, and later plummeted by 31854.13% in 2023.
  • Over the past 5 years, Theravance Biopharma's Net Income towards Common Stockholders (Quarter) stood at $25.8 million in 2021, then plummeted by 84.9% to $3.9 million in 2022, then plummeted by 318.54% to -$8.5 million in 2023, then crashed by 171.45% to -$23.1 million in 2024, then surged by 115.65% to $3.6 million in 2025.
  • Its Net Income towards Common Stockholders was $3.6 million in Q3 2025, compared to $54.8 million in Q2 2025 and -$13.5 million in Q1 2025.